Weight loss drugs, compounding, vitamin D, and AI all piqued readers’ interest — and sometimes, ire — this past year.

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

If Trump wants to improve Americans’ health, as he says, expanding coverage of weight-loss drugs should be a priority. With ...

For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...

We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 491.86% and ...

At least 29 patent suits were filed in the District of New Jersey in November, reflecting a jump from the rate of 18 suits ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

First-in-human results for three investigational inhibitors show anti-tumor activity without unmanageable effects on blood glucose.